Last reviewed · How we verify
NCT06900686
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
trial testing PD1 Inhibitor in Rectal Cancer in 458 participants. Completed in 23 March 2025.
20 September 2022
Quick facts
| Lead sponsor | Yanhong Deng |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 458 |
| Start date | 20 March 2013 |
| Primary completion | 20 September 2022 |
| Estimated completion | 23 March 2025 |
Drugs / interventions tested
- PD1 Inhibitor — full drug profile →
Conditions studied
- Rectal Cancer — all drugs for Rectal Cancer →
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
Yanhong Deng — full company profile →
Who can join
Eligibility, any sex, with Rectal Cancer or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a single-center retrospective study. Eligible patients receiving PD-1 inhibitor treatment will enrolled.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06900686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PD1 Inhibitor
Trials testing the same drug.
- NCT06896422 — Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC · Phase 1 · recruiting
- NCT06957977 — A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advance · Phase 2 · not yet recruiting
- NCT04093323 — Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HL · Phase 2 · terminated
- NCT04639245 — Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the T · Phase 1, PHASE2 · terminated
Other recruiting trials for Rectal Cancer
Currently open trials in the same condition.
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Other Yanhong Deng trials
Trials by the same sponsor.
- NCT06779474 — Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver M · not yet recruiting
- NCT05360277 — Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT05427669 — Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) · Phase 3 · not yet recruiting
- NCT06898359 — Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer · completed
- NCT05450029 — Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06900686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yanhong Deng
- Last refreshed: 28 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06900686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing